The Department of Radiation Oncology at Renji Hospital was established in 2005. It treats various common malignant tumors with radiotherapy and comprehensive treatment, and has subspecialties including head and neck, thoracic, and abdominopelvic oncology. It has standard standardized wards with 48 beds, expandable to 85 beds, making it one of the hospitals with more beds among tertiary comprehensive hospitals in Shanghai. The department has strong technical expertise and routinely performs three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, VMAT volumetric rotational therapy, TOMO, three-dimensional brachytherapy, stereotactic radiotherapy, and ART adaptive radiotherapy. It is also the institution of the second president of the Radiation Oncology Branch of the Shanghai Medical Doctor Association and has a well-structured team of physicians. The department develops in a balanced manner in clinical care, education, and research. While ensuring patients receive high-quality and efficient clinical treatment, it also conducts clinical trials and basic research. It has two full-time research personnel and is a master's degree training site in Radiation Oncology at Shanghai Jiao Tong University School of Medicine. It is also a standardized training base for radiation oncology residents in Shanghai and a standardized training base for radiation oncology specialists in Shanghai. It is also one of the team members of the Joint Visiting Scholar Program in Radiation Oncology at Shanghai Jiao Tong University School of Medicine, and each year accepts visiting physicians and physicists for training from multiple domestic hospitals. In terms of clinical application, from its establishment to January 2024, the department had treated a total of 28,286 patients receiving initial radiotherapy, involving more than 34 disease types including pediatric tumors. The top eight malignant tumors among initially treated cases were breast cancer, lung cancer, cervical cancer, esophageal cancer, rectal cancer, nasopharyngeal carcinoma, prostate cancer, and brain glioma. In 2023, the number of discharged patients in the Department of Radiation Oncology was 3,620 person-times, the number of outpatient visits was 22,677 person-times, and the number of patients receiving radiotherapy was 2,925 cases. The number of radiotherapy sessions ranked among the top 3 among comprehensive tertiary hospitals in Shanghai. In terms of platform equipment, the Department of Radiation Oncology is currently equipped with 5 medical linear accelerators capable of performing IMRT, IGRT, SBRT, and ART (adaptive radiotherapy) (1 United Imaging CT-guided ring accelerator Halos, 1 Tomo Radixact, 1 Varian Edge, 1 Varian ring accelerator Halcyon, 1 Elekta Synergy VMAT), 1 head stereotactic gamma knife, 1 three-dimensional brachytherapy afterloader, 1 dedicated large-bore 4DCT simulation positioning machine for radiotherapy, and 5 brands of dedicated radiotherapy treatment planning systems (Philips Pinnacle, Varian Eclipse, Tomotherapy, Elekta Oncentra, United Imaging uTPS, totaling more than 39 workstations). It is also equipped with IBA second-generation three-dimensional water tank, IBA Compass, IBA Matrixx, PTW Octavius multichannel three-dimensional dose verification system, IBA reference-grade dosimeter, Vidar self-developing film scanner, and RIT complete set of film analysis software and other corresponding proton therapy physics quality control equipment. It is also equipped with a customized integrated oncology information platform for radiotherapy. In terms of talent echelon, the center currently has 18 physicians, including 6 with doctoral degrees and 6 doctoral students in progress; 3 with senior professional titles, 5 with associate senior titles, 8 attending physicians, and 3 residents; 18 nurses in the inpatient department and 2 in the outpatient department; 7 physicists; and 22 technologists. There are 2 full-time research personnel. Multiple clinical subspecialty directions have been established with dedicated responsible persons, including thoracic tumors, head and neck tumors, breast tumors, gastrointestinal tumors, genitourinary system tumors, and nervous system tumors. In terms of prior foundation, over the past 5 years, the center has achieved fruitful innovative results in clinical and basic research. Over the past five years, it has obtained various research projects, including a total of 8 National Natural Science Foundation of China projects: National Natural Science Foundation of China Youth Project (Project Number: 81903129) Mechanism study on RASSF2 regulating CD103+ dendritic cell infiltration in the tumor microenvironment and affecting radiotherapy efficacy; National Natural Science Foundation of China Youth Project (Project Number: 81802626), Study on the role and mechanism of CircRNA XPO4 as a ceRNA in regulating cisplatin resistance in triple-negative breast cancer; National Natural Science Foundation of China Youth Project (Project Number: 82303278) Mechanism study on platelet-derived 5-HT promoting pancreatic cancer progression by regulating the pancreatic cancer microenvironment through HTR7 and 5-HT-mediated post-translational modification; National Natural Science Foundation of China General Program (Project Number: 81972854), Study on the role and mechanism of LINC00273/ZEB1 in radiotherapy-induced ferroptosis in triple-negative breast cancer cells; National Natural Science Foundation of China Youth Project (Project Number: 82102829), Mechanism study on CDK7 inhibitor THZ1 regulating triple-negative breast cancer growth inhibition and radiotherapy sensitivity through transcription factor MYC; National Natural Science Foundation of China Youth Project (Project Number: 82403800) Mechanism study on gut microbiota-host co-metabolite pCS mediating macrophage fatty acid oxidation to promote neoadjuvant radiotherapy resistance in rectal cancer; National Natural Science Foundation of China General Program (Project Number: 31970745) Regulatory effect of vascular basement membrane on neutrophil extravasation and its molecular mechanism; National Natural Science Foundation of China General Program (Project Number: 82272747) Single-cell RNA sequencing-based analysis of the role and mechanism of USP29/ZEB1 in radiotherapy resistance of triple-negative breast cancer; total funding 2.975 million yuan. It has carried out 5 Shanghai Municipal Science and Technology Commission projects, including the Shanghai Natural Science Foundation project "Mechanism study on ABCA7 gene mutation regulating pancreatic cancer radiotherapy sensitivity through lncRNA TMEM191A" and the Shanghai Natural Science Foundation General Program "Single-cell dimensional analysis of the role and mechanism of DGCR8 inhibiting T lymphocyte intestinal homing to alleviate radiation-induced intestinal injury"; and participated in 1 National Key R&D Program project of the National 13th Five-Year Research Plan for head gamma knife evaluation and preliminary data analysis, with a total of 26 projects, 3 drug clinical trials, and more than 10 ITT studies, and published 46 SCI papers. It led the development and clinical research of China's first CT-guided ring accelerator and successfully obtained NMPA certification. It led the development and clinical application of China's first domestic integrated oncology radiotherapy information platform, passing the national electronic medical record level 6 review.